HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Unilever Continues Full Steam Ahead With ‘Natural’ Moves, Projects Up To 5% USG For Full Year

This article was originally published in The Rose Sheet

Executive Summary

Currency headwinds drove a 5% decline in fiscal 2018 first-half turnover, but underlying sales growth was 2.7% excluding the firm’s now divested spreads business. In a challenging global environment, Unilever continues to bet on natural investments to propel growth in its beauty unit and others. 

You may also be interested in...



Unilever To Slim Down Further With Ice Cream Separation

Unilever's ‘Fewer Things Better’ Growth Action Plan is in motion as the London-based company announces plans to separate out its Ice Cream division to accelerate growth and achieve cost savings of around €800m over the next three years.

Unilever’s Schmidt’s Brand Expands To New Category: ‘Home Care Can Be Self Care’

Founded in 2010 as a natural deodorant brand, Schmidt’s is extending its “plant-powered” formulation expertise to home care with the launch of Cleaning Vinegar Multi-Surface Spray and Concentrated Laundry Detergent.

Unilever Primes Mob Of New Brands To Be ‘Future Fit’ In Hyper-Fragmented World

Unilever’s growth focus will continue to be its core assets, but in a hyper-fragmented global marketplace the firm is escalating new brand creation, with more than a dozen in the pipeline. The firm’s Alan Jope, president of personal care, discusses.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS121735

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel